N-cyclopropylcyclobutanecarboxamide | 915403-77-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyclopropylcyclobutanecarboxamide
• 英文别名: Cyclobutanecarboxamide, N-cyclopropyl-
• CAS: 915403-77-9
• 化学式: C₈H₁₃NO
• mdl: MFCD19159629
• 分子量: 139.197
• InChiKey: UZNQBNCEQKQIIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-2-(thiophen-2-yl)-propanehydrazide 、 N-cyclopropylcyclobutanecarboxamide 在 三氟甲烷磺酸甲酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 48.5h， 以29%的产率得到3-cyclobutyl-4-cyclopropyl-5-[2-(thiophen-2-yl)propan-2-yl]-4H-1,2,4-triazole
  参考文献：
  名称：

  用于治疗2型糖尿病的强力和口服活性人11β-羟基类固醇脱氢酶1型抑制剂的发现和生物学评估。

  摘要：

  我们合成并评估了新型的5- [2-（噻吩-2-基）丙-2-基] -4H-1,2,4-三唑衍生物，作为11β-羟基类固醇脱氢酶1型（11β-HSD1）抑制剂。噻吩环和1,2,4-三唑环上的取代基的优化产生了3,4-二环丙基-5- {2- [3-氟-3-（三氟甲基）噻吩-2-基]丙烷-2- yl} -4H-1,2,4-三唑单盐酸盐（9a），对人11β-HSD1具有强效和选择性抑制活性。化合物9a对人和小鼠肝微粒体也具有代谢稳定性。对糖尿病ob / ob小鼠口服9a降低了脂肪组织中的皮质酮水平，从而以剂量依赖的方式降低了血浆葡萄糖和胰岛素水平。

  DOI：

  10.1248/cpb.c19-00211
• 作为产物：
  描述：

  环丙胺 、 环丁基甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-cyclopropylcyclobutanecarboxamide
  参考文献：
  名称：

  Cooperative Photoredox and Cobalt‐catalyzed Acceptorless Dehydrogenative Functionalization of Cyclopropylamides towards Allylic N,O‐Acyl‐acetal Derivatives

  摘要：

  We disclose herein a novel photoredox and cobalt co‐catalyzed ring‐opening/acceptorless dehydrogenative functionalization of mono‐donor cyclopropanes, which providing a sustainable and atom‐economic approach to rapidly assemble a wide range of allylic N,O‐acyl‐acetal derivatives. The optimized conditions accommodate assorted cycloalkylamides and primary, secondary and tertiary alcohols, with applications in late‐stage functionalization of pharmaceutically relevant compounds, stimulating the further utility in medicinal chemistry. Moreover, selective nucleophilic substitutions with various carbon nucleophiles were succeed in a one‐pot fashion, offering a reliable avenue to access some cyclic and acyclic derivatives.

  DOI：

  10.1002/anie.202401579

文献信息

• [EN] SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS<br/>[FR] TRIAZINONES SUBSTITUÉES EN TANT QU'AGONISTES DU RÉCEPTEUR DE L'HORMONE THYROÏDIENNE
  申请人：ECCOGENE SHANGHAI CO LTD

  公开号：WO2021143706A1

  公开（公告）日：2021-07-22

  The application relates to a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I') or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

  该申请涉及式(I')或(I)的化合物，或其药物可接受的盐、水合物、溶剂化物、前药、立体异构体或互变异构体，其可调节甲状腺激素受体的活性，包含式(I')或(I)的化合物的药物组合物，以及用于治疗或预防由甲状腺激素调节的疾病或失调的方法。
• Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
  作者：Takanori Koike、Ryota Shiraki、Daisuke Sasuga、Mitsuru Hosaka、Tomoaki Kawano、Hiroki Fukudome、Kazuo Kurosawa、Ayako Moritomo、Shinya Mimasu、Hirofumi Ishii、Seiji Yoshimura

  DOI：10.1248/cpb.c19-00211

  日期：2019.8.1

  We synthesized and evaluated novel 5-[2-(thiophen-2-yl)propan-2-yl]-4H-1,2,4-triazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. Optimization of the thiophene ring and the substituents on the 1,2,4-triazole ring produced 3,4-dicyclopropyl-5-2-[3-fluoro-5-(trifluoromethyl)thiophen-2-yl]propan-2-yl}-4H-1,2,4-triazole monohydrochloride (9a), which showed potent and

  我们合成并评估了新型的5- [2-（噻吩-2-基）丙-2-基] -4H-1,2,4-三唑衍生物，作为11β-羟基类固醇脱氢酶1型（11β-HSD1）抑制剂。噻吩环和1,2,4-三唑环上的取代基的优化产生了3,4-二环丙基-5- 2- [3-氟-3-（三氟甲基）噻吩-2-基]丙烷-2- yl} -4H-1,2,4-三唑单盐酸盐（9a），对人11β-HSD1具有强效和选择性抑制活性。化合物9a对人和小鼠肝微粒体也具有代谢稳定性。对糖尿病ob / ob小鼠口服9a降低了脂肪组织中的皮质酮水平，从而以剂量依赖的方式降低了血浆葡萄糖和胰岛素水平。
• Cooperative Photoredox and Cobalt‐catalyzed Acceptorless Dehydrogenative Functionalization of Cyclopropylamides towards Allylic N,O‐Acyl‐acetal Derivatives
  作者：Haohao Huang、Xinjun Luan、Zhijun Zuo

  DOI：10.1002/anie.202401579

  日期：——

  We disclose herein a novel photoredox and cobalt co‐catalyzed ring‐opening/acceptorless dehydrogenative functionalization of mono‐donor cyclopropanes, which providing a sustainable and atom‐economic approach to rapidly assemble a wide range of allylic N,O‐acyl‐acetal derivatives. The optimized conditions accommodate assorted cycloalkylamides and primary, secondary and tertiary alcohols, with applications in late‐stage functionalization of pharmaceutically relevant compounds, stimulating the further utility in medicinal chemistry. Moreover, selective nucleophilic substitutions with various carbon nucleophiles were succeed in a one‐pot fashion, offering a reliable avenue to access some cyclic and acyclic derivatives.